Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
October 2020
-
Media ReleaseNovartis receives US Food and Drug Administration (FDA) Orphan Drug Designation for branaplam (LMI070) in Huntington’s disease (HD)Huntington’s disease is a rare, inherited neurodegenerative disease that leads to progressive disability and deathThere are no approved disease modifying therapies that delay disease onset or slow…
-
Key ReleaseNovartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterolIf approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1Cardiovascular disease (CVD) claims 3.9…
-
Media ReleaseNovartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)The European Medicines Agency has granted iptacopan a priority medicines (PRIME) designation in C3 glomerulopathy (C3G). PRIME is granted for medicines that may offer major therapeutic advance…
-
Featured NewsWorld Sight Day 2020
Learn how we’re working with partners like the International Agency for the Prevention of Blindness to eliminate preventable blindness.
-
Meet a visionary who beat the odds to realize his vision of inclusive eye care
Dr. Theophile Tuyisabe is one of only 18 ophthalmologists in Rwanda. We spoke with him about how he does it.
-
Media ReleaseNew Phase III analysis demonstrates Novartis Beovu® showed improvement in best-corrected visual acuity in wet AMD patients with early persistent fluidIn a post-hoc analysis of HAWK and HARRIER, fewer Beovu (brolucizumab) patients had early persistent fluid (12.5% vs. 20.4% of aflibercept patients), defined as the presence of intra-retinal fluid…
-
Media ReleaseZolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievementNearly two-thirds of patients (65.6%) in STR1VE-EU have already achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6…
September 2020
-
Featured NewsLife Science Companies and the Bill & Melinda Gates Foundation: Joint Communique
Commitments to expanded global access for COVID-19 diagnostics, therapeutics, and vaccines.
-
Featured NewsWorld Heart Day 2020: From our heart to yours
September 29 is World Heart Day. For the past six decades, Novartis has been working to advance heart health around the world.
-
Chagas disease: Breaking the silence
Explaining Chagas disease through the stories of patients in Latin America.
-
Key ReleaseNovartis Provides Update on AVXS-101 Intrathecal Clinical Development ProgramNovartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (IT) formulation in older patients with SMA to further support registration Basel,…
-
Speaking Up in CML
Lisa, a patient living with CML, shares her experience and discusses the importance of speaking up about unmet needs in your disease.
Pagination
- ‹ Previous page
- 1
- …
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- …
- 152
- › Next page